Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Salute | Prodotti farmaceutici | 672,12 Mrd USD | 79,9x | 1,19 | 743,95 USD | 2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 37,7% Rialzo | Fai l’upgrade a Pro+ | |
UnitedHealth | NYSE | Salute | Fornitori e servizi sanitari | 542,86 Mrd USD | 38x | -1,15 | 589,46 USD | 2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 7,6% Rialzo | Fai l’upgrade a Pro+ | |
Novo Nordisk ADR | NYSE | Salute | Prodotti farmaceutici | 460 Mrd USD | 34,6x | 1,24 | 104,08 USD | 1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 45,6% Rialzo | Fai l’upgrade a Pro+ | |
J&J | NYSE | Salute | Prodotti farmaceutici | 367,50 Mrd USD | 25x | -0,46 | 152,72 USD | -0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14,4% Rialzo | Fai l’upgrade a Pro+ | |
AbbVie | NYSE | Salute | Prodotti farmaceutici | 293,35 Mrd USD | 57,8x | -2,68 | 165,85 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24,9% Rialzo | Fai l’upgrade a Pro+ | |
Merck&Co | NYSE | Salute | Prodotti farmaceutici | 247,58 Mrd USD | 20,4x | 0,12 | 97,77 USD | 1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 39,8% Rialzo | Fai l’upgrade a Pro+ | |
Roche Holding Participation | OTC Markets | Salute | Prodotti farmaceutici | 238,87 Mrd USD | 19,9x | -5,94 | 281,96 USD | -0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Roche Holding ADR | OTC Markets | Salute | Prodotti farmaceutici | 238,87 Mrd USD | 19,9x | -5,94 | 35,27 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 33,9% Rialzo | Fai l’upgrade a Pro+ | |
Novartis | OTC Markets | Salute | Prodotti farmaceutici | 205,55 Mrd USD | 11,9x | 0,13 | 105 USD | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -21% Ribasso | Fai l’upgrade a Pro+ | |
Novartis ADR | NYSE | Salute | Prodotti farmaceutici | 205,55 Mrd USD | 11,9x | 0,13 | 102,64 USD | -0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 16,2% Rialzo | Fai l’upgrade a Pro+ | |
Abbott Labs | NYSE | Salute | Attrezzature e forniture medicali | 201,37 Mrd USD | 35,2x | 2,91 | 115,97 USD | -1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 11% Rialzo | Fai l’upgrade a Pro+ | |
AstraZeneca PLC | OTC Markets | Salute | Prodotti farmaceutici | 195,93 Mrd USD | 30,2x | 3,07 | 126,58 USD | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
AstraZeneca ADR | NASDAQ | Salute | Prodotti farmaceutici | 195,93 Mrd USD | 30,2x | 3,07 | 63,71 USD | -0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 42,6% Rialzo | Fai l’upgrade a Pro+ | |
Thermo Fisher Scientific | NYSE | Salute | Attrezzature e forniture medicali | 194,82 Mrd USD | 31,8x | 7,02 | 511,69 USD | 0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 28,7% Rialzo | Fai l’upgrade a Pro+ | |
Intuitive Surgical | NASDAQ | Salute | Attrezzature e forniture medicali | 190,58 Mrd USD | 84,4x | 1,81 | 536,50 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 1,8% Rialzo | Fai l’upgrade a Pro+ | |
Danaher | NYSE | Salute | Attrezzature e forniture medicali | 166,79 Mrd USD | 43,7x | -1,25 | 231,53 USD | 0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24,1% Rialzo | Fai l’upgrade a Pro+ | |
Amgen | NASDAQ | Salute | Prodotti farmaceutici | 150,62 Mrd USD | 35,5x | -0,81 | 280,34 USD | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 19,7% Rialzo | Fai l’upgrade a Pro+ | |
Stryker | NYSE | Salute | Attrezzature e forniture medicali | 146,46 Mrd USD | 40,7x | 1,08 | 383,75 USD | -1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 2,9% Rialzo | Fai l’upgrade a Pro+ | |
Pfizer | NYSE | Salute | Prodotti farmaceutici | 141,28 Mrd USD | 33,2x | -0,55 | 24,91 USD | -0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 27,5% Rialzo | Fai l’upgrade a Pro+ | |
Boston Scientific | NYSE | Salute | Attrezzature e forniture medicali | 132,07 Mrd USD | 73,5x | 1,52 | 89,72 USD | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 8,5% Rialzo | Fai l’upgrade a Pro+ | |
Sanofi ADR | NASDAQ | Salute | Prodotti farmaceutici | 119,95 Mrd USD | 25,5x | -0,51 | 47,80 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 31,3% Rialzo | Fai l’upgrade a Pro+ | |
Bristol-Myers Squibb | NYSE | Salute | Prodotti farmaceutici | 117,72 Mrd USD | -16,2x | 0,08 | 58,01 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 3% Rialzo | Fai l’upgrade a Pro+ | |
Vertex | NASDAQ | Salute | Ricerca medica e biotecnologica | 114,91 Mrd USD | -240,2x | 2,19 | 447,74 USD | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 16,4% Rialzo | Fai l’upgrade a Pro+ | |
Essilor International SA | OTC Markets | Salute | Attrezzature e forniture medicali | 112,15 Mrd USD | 46x | -12,95 | 123,59 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -2,2% Ribasso | Fai l’upgrade a Pro+ | |
Gilead | NASDAQ | Salute | Prodotti farmaceutici | 110,06 Mrd USD | 874,4x | -8,93 | 88,29 USD | 0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10% Rialzo | Fai l’upgrade a Pro+ | |
Medtronic | NYSE | Salute | Attrezzature e forniture medicali | 107,45 Mrd USD | 25,5x | 2,99 | 83,73 USD | -1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 13,5% Rialzo | Fai l’upgrade a Pro+ | |
Elevance Health | NYSE | Salute | Fornitori e servizi sanitari | 91,93 Mrd USD | 14,4x | 1,58 | 396,31 USD | 0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 31,9% Rialzo | Fai l’upgrade a Pro+ | |
Cigna | NYSE | Salute | Fornitori e servizi sanitari | 89,09 Mrd USD | 29,9x | -0,73 | 320,34 USD | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24% Rialzo | Fai l’upgrade a Pro+ | |
CSL | OTC Markets | Salute | Prodotti farmaceutici | 85,79 Mrd USD | 32,6x | 1,61 | 88,80 USD | 0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24,7% Rialzo | Fai l’upgrade a Pro+ | |
HCA | NYSE | Salute | Fornitori e servizi sanitari | 83,65 Mrd USD | 14,6x | 1,57 | 330,34 USD | -1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 20,5% Rialzo | Fai l’upgrade a Pro+ |